Spruce Biosciences is a biotechnology business based in the US. Spruce Biosciences shares (SPRB) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.07 – a decrease of 5.98% over the previous week. Spruce Biosciences employs 21 staff and has a trailing 12-month revenue of around $4.9 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.07 |
|---|---|
| 52-week range | $0.06 - $0.87 |
| 50-day moving average | $0.28 |
| 200-day moving average | $0.42 |
| Wall St. target price | $0.75 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.29 |
Historical closes compared with the close of $0.0739 from 2025-05-02
| 1 week (2025-04-29) | -10.86% |
|---|---|
| 1 month (2025-04-04) | -73.66% |
| 3 months (2025-02-06) | -81.77% |
| 6 months (2024-11-06) | -86.42% |
| 1 year (2024-05-06) | -90.20% |
|---|---|
| 2 years (2023-05-05) | -96.79% |
| 3 years (2022-05-06) | 1.61 |
| 5 years (2020-05-02) | N/A |
| Revenue TTM | $4.9 million |
|---|---|
| Gross profit TTM | $-41,507,000 |
| Return on assets TTM | -47.06% |
| Return on equity TTM | -100.7% |
| Profit margin | 0% |
| Book value | $0.68 |
| Market Capitalization | $3.3 million |
TTM: trailing 12 months
We're not expecting Spruce Biosciences to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Spruce Biosciences's shares have ranged in value from as little as $0.057 up to $0.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Spruce Biosciences's is 2.39. This would suggest that Spruce Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Spruce Biosciences's beta into context you can compare it against those of similar companies.
Spruce Biosciences, Inc. , a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .